ABSTRACT Objectives: To measure the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes . Study Design: Retrospective study of patients diagnosed with MDS in the Surveillance, Epidemiology and End Results Program registry, clinical trial evidence for MDS therapies, and claims data.